- Home
- ARI vs OCS Comparison
ARI vs OCS Comparison
Compare ARI & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARI
- OCS
- Stock Information
- Founded
- ARI 2009
- OCS 2003
- Country
- ARI United States
- OCS Switzerland
- Employees
- ARI N/A
- OCS N/A
- Industry
- ARI Real Estate Investment Trusts
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- ARI Real Estate
- OCS Health Care
- Exchange
- ARI Nasdaq
- OCS Nasdaq
- Market Cap
- ARI 1.1B
- OCS 956.4M
- IPO Year
- ARI 2009
- OCS N/A
- Fundamental
- Price
- ARI $9.73
- OCS $17.79
- Analyst Decision
- ARI Hold
- OCS Strong Buy
- Analyst Count
- ARI 5
- OCS 3
- Target Price
- ARI $10.08
- OCS $35.33
- AVG Volume (30 Days)
- ARI 1.4M
- OCS 14.6K
- Earning Date
- ARI 07-29-2025
- OCS 08-26-2025
- Dividend Yield
- ARI 10.29%
- OCS N/A
- EPS Growth
- ARI N/A
- OCS N/A
- EPS
- ARI N/A
- OCS N/A
- Revenue
- ARI $276,844,000.00
- OCS $847,333.00
- Revenue This Year
- ARI $32.11
- OCS $10.23
- Revenue Next Year
- ARI $19.41
- OCS $912.87
- P/E Ratio
- ARI N/A
- OCS N/A
- Revenue Growth
- ARI 104.64
- OCS N/A
- 52 Week Low
- ARI $7.70
- OCS $10.79
- 52 Week High
- ARI $11.20
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- ARI 44.67
- OCS 36.66
- Support Level
- ARI $9.80
- OCS $17.71
- Resistance Level
- ARI $10.04
- OCS $18.20
- Average True Range (ATR)
- ARI 0.17
- OCS 0.41
- MACD
- ARI -0.02
- OCS -0.12
- Stochastic Oscillator
- ARI 35.45
- OCS 7.94
About ARI Apollo Commercial Real Estate Finance Inc
Apollo Commercial Real Estate Finance Inc is a real estate investment trust that primarily originates, invests in, acquires, and manages commercial first-mortgage loans, subordinate financings, commercial mortgage-backed securities, and other real estate-related debt investments. The subordinate loans and first-mortgage loans account for the vast majority of the portfolio on a cost basis. Property types include residential, retail, healthcare, office, mixed-use, hotel, industrial, multifamily, securities, and other, with residential properties and hotels representing the highest property value. More than a third of the properties are located in New York City, with the other properties located across other regions of the United States, as well as other countries.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.